| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 19 | 2022 | 724 | 3.410 |
Why?
|
| Glioma | 11 | 2022 | 266 | 2.630 |
Why?
|
| Muscle, Skeletal | 14 | 2018 | 426 | 1.640 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2021 | 421 | 1.350 |
Why?
|
| Brain | 9 | 2021 | 2053 | 1.190 |
Why?
|
| Autopsy | 5 | 2021 | 98 | 1.170 |
Why?
|
| Neuroblastoma | 7 | 2021 | 354 | 1.140 |
Why?
|
| Muscular Diseases | 5 | 2018 | 59 | 1.110 |
Why?
|
| Alzheimer Disease | 4 | 2017 | 338 | 1.010 |
Why?
|
| Mutation | 13 | 2022 | 3792 | 0.980 |
Why?
|
| Myasthenic Syndromes, Congenital | 6 | 2021 | 35 | 0.950 |
Why?
|
| Humans | 103 | 2022 | 80814 | 0.940 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2020 | 82 | 0.910 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2020 | 78 | 0.880 |
Why?
|
| Placenta | 2 | 2022 | 165 | 0.870 |
Why?
|
| Megakaryocytes | 1 | 2021 | 37 | 0.870 |
Why?
|
| Telomerase | 1 | 2021 | 52 | 0.860 |
Why?
|
| Biopsy | 6 | 2022 | 1124 | 0.860 |
Why?
|
| Microvessels | 1 | 2021 | 68 | 0.840 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 60 | 0.820 |
Why?
|
| Immunohistochemistry | 14 | 2022 | 1714 | 0.780 |
Why?
|
| Pathology, Surgical | 1 | 2019 | 12 | 0.770 |
Why?
|
| Microbiological Techniques | 1 | 2019 | 24 | 0.760 |
Why?
|
| Biomarkers, Tumor | 7 | 2022 | 1409 | 0.750 |
Why?
|
| Cerebellar Neoplasms | 3 | 2017 | 36 | 0.730 |
Why?
|
| Rhabdoid Tumor | 2 | 2016 | 19 | 0.710 |
Why?
|
| Pathology, Clinical | 1 | 2018 | 32 | 0.700 |
Why?
|
| Schwann Cells | 3 | 2020 | 34 | 0.700 |
Why?
|
| Neurilemmoma | 2 | 2021 | 33 | 0.680 |
Why?
|
| Hemangioblastoma | 2 | 2017 | 12 | 0.670 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 7 | 0.660 |
Why?
|
| Male | 48 | 2021 | 39380 | 0.660 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2018 | 289 | 0.660 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 40 | 0.660 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 45 | 0.650 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 406 | 0.640 |
Why?
|
| Neoplasms | 2 | 2022 | 2684 | 0.640 |
Why?
|
| Glioblastoma | 4 | 2015 | 235 | 0.630 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 76 | 0.620 |
Why?
|
| Muscular Dystrophies | 4 | 2013 | 53 | 0.610 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2016 | 3 | 0.600 |
Why?
|
| Glycogen Storage Disease | 1 | 2016 | 5 | 0.600 |
Why?
|
| Female | 51 | 2022 | 42421 | 0.590 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 530 | 0.590 |
Why?
|
| Myoepithelioma | 1 | 2015 | 11 | 0.580 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2020 | 125 | 0.580 |
Why?
|
| Myofibrils | 2 | 2014 | 22 | 0.570 |
Why?
|
| Niemann-Pick Disease, Type C | 1 | 2015 | 3 | 0.560 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 104 | 0.550 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 144 | 0.550 |
Why?
|
| Nerve Sheath Neoplasms | 3 | 2020 | 17 | 0.550 |
Why?
|
| Complement C4 | 1 | 2014 | 9 | 0.540 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 420 | 0.540 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2014 | 20 | 0.540 |
Why?
|
| Sella Turcica | 2 | 2019 | 17 | 0.540 |
Why?
|
| Middle Aged | 29 | 2022 | 23934 | 0.540 |
Why?
|
| Myositis | 1 | 2014 | 16 | 0.540 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 101 | 0.530 |
Why?
|
| Vesicular Transport Proteins | 4 | 2018 | 63 | 0.530 |
Why?
|
| Astrocytoma | 3 | 2022 | 81 | 0.530 |
Why?
|
| Pituitary Neoplasms | 2 | 2019 | 62 | 0.520 |
Why?
|
| Temporal Lobe | 1 | 2015 | 151 | 0.510 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 12 | 0.510 |
Why?
|
| Muscle Proteins | 7 | 2014 | 133 | 0.510 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2014 | 42 | 0.500 |
Why?
|
| Membrane Proteins | 9 | 2015 | 1159 | 0.490 |
Why?
|
| Seizures | 1 | 2015 | 268 | 0.460 |
Why?
|
| Paraganglioma | 2 | 2019 | 13 | 0.460 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 99 | 0.460 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 6211 | 0.450 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 373 | 0.440 |
Why?
|
| Organ Transplantation | 1 | 2015 | 253 | 0.440 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 317 | 0.430 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1882 | 0.430 |
Why?
|
| Neurofibromatosis 1 | 2 | 2022 | 36 | 0.420 |
Why?
|
| Hippocampus | 1 | 2015 | 424 | 0.420 |
Why?
|
| Adolescent | 11 | 2021 | 8656 | 0.410 |
Why?
|
| Aged | 19 | 2021 | 17464 | 0.410 |
Why?
|
| Cardiomyopathies | 4 | 2021 | 221 | 0.390 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 19 | 0.390 |
Why?
|
| Adult | 24 | 2021 | 24602 | 0.390 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2017 | 177 | 0.380 |
Why?
|
| Pneumocephalus | 1 | 2009 | 9 | 0.380 |
Why?
|
| Embolism, Air | 1 | 2009 | 21 | 0.380 |
Why?
|
| Nervous System Neoplasms | 1 | 2009 | 11 | 0.380 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2009 | 1 | 0.380 |
Why?
|
| Retrospective Studies | 7 | 2021 | 7532 | 0.380 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2008 | 4 | 0.360 |
Why?
|
| Craniopharyngioma | 1 | 2009 | 11 | 0.360 |
Why?
|
| World Health Organization | 1 | 2009 | 99 | 0.360 |
Why?
|
| Transcription Factors | 4 | 2022 | 1484 | 0.360 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 1035 | 0.360 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2018 | 137 | 0.360 |
Why?
|
| Diagnosis, Differential | 8 | 2021 | 1509 | 0.350 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2008 | 10 | 0.350 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 62 | 0.350 |
Why?
|
| Child | 12 | 2021 | 6538 | 0.350 |
Why?
|
| Nerve Tissue Proteins | 6 | 2018 | 494 | 0.350 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2008 | 67 | 0.350 |
Why?
|
| Laminin | 3 | 2018 | 81 | 0.350 |
Why?
|
| Child, Preschool | 10 | 2021 | 3522 | 0.340 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 101 | 0.340 |
Why?
|
| Mice | 29 | 2020 | 10810 | 0.340 |
Why?
|
| Oligodendroglia | 2 | 2020 | 122 | 0.330 |
Why?
|
| Hemorrhage | 1 | 2009 | 233 | 0.330 |
Why?
|
| Disease Models, Animal | 10 | 2016 | 2157 | 0.320 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 682 | 0.320 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2007 | 21 | 0.310 |
Why?
|
| Dacarbazine | 3 | 2013 | 101 | 0.310 |
Why?
|
| rho-Associated Kinases | 2 | 2019 | 158 | 0.300 |
Why?
|
| Dementia, Vascular | 1 | 2006 | 4 | 0.300 |
Why?
|
| Animals | 34 | 2020 | 25628 | 0.290 |
Why?
|
| Spinal Diseases | 1 | 2006 | 45 | 0.290 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 336 | 0.290 |
Why?
|
| Sepsis | 1 | 2009 | 273 | 0.290 |
Why?
|
| Cerebral Infarction | 1 | 2006 | 54 | 0.290 |
Why?
|
| Ganglioneuroma | 1 | 2005 | 10 | 0.280 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 1189 | 0.280 |
Why?
|
| Cauda Equina | 1 | 2005 | 13 | 0.280 |
Why?
|
| Liposarcoma | 1 | 2005 | 10 | 0.280 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2017 | 25 | 0.280 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 2 | 2019 | 198 | 0.270 |
Why?
|
| Dura Mater | 2 | 2020 | 44 | 0.270 |
Why?
|
| Neuromuscular Junction | 3 | 2021 | 77 | 0.270 |
Why?
|
| Infant | 8 | 2020 | 2928 | 0.270 |
Why?
|
| Amyloid beta-Peptides | 2 | 2021 | 162 | 0.260 |
Why?
|
| ErbB Receptors | 2 | 2021 | 475 | 0.260 |
Why?
|
| Young Adult | 6 | 2021 | 5713 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2020 | 3116 | 0.250 |
Why?
|
| Stress, Physiological | 2 | 2020 | 224 | 0.250 |
Why?
|
| Myoblasts | 4 | 2014 | 29 | 0.250 |
Why?
|
| Motor Neurons | 2 | 2017 | 155 | 0.240 |
Why?
|
| Cell Count | 2 | 2021 | 191 | 0.240 |
Why?
|
| Fatal Outcome | 5 | 2013 | 283 | 0.240 |
Why?
|
| Vasculitis | 2 | 2020 | 38 | 0.240 |
Why?
|
| Myocardium | 3 | 2018 | 516 | 0.240 |
Why?
|
| Lymphoma | 2 | 2018 | 258 | 0.240 |
Why?
|
| Spinal Nerve Roots | 1 | 2002 | 17 | 0.240 |
Why?
|
| Neurofibromatoses | 1 | 2002 | 9 | 0.240 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2002 | 10 | 0.230 |
Why?
|
| Tissue Fixation | 1 | 2022 | 39 | 0.230 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 77 | 0.230 |
Why?
|
| Formaldehyde | 1 | 2022 | 52 | 0.230 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 2 | 2021 | 2 | 0.230 |
Why?
|
| Monosomy | 1 | 2022 | 12 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 3 | 2021 | 917 | 0.220 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2022 | 6 | 0.220 |
Why?
|
| Muscle Development | 2 | 2014 | 38 | 0.220 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 6 | 0.220 |
Why?
|
| Chondrosarcoma | 1 | 2022 | 47 | 0.220 |
Why?
|
| Specimen Handling | 1 | 2022 | 91 | 0.220 |
Why?
|
| Synaptotagmin II | 1 | 2021 | 1 | 0.220 |
Why?
|
| Chloroquine | 1 | 2021 | 12 | 0.220 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 10 | 0.210 |
Why?
|
| Cystadenoma, Papillary | 1 | 2021 | 8 | 0.210 |
Why?
|
| Pelvic Neoplasms | 2 | 2012 | 42 | 0.210 |
Why?
|
| Antimalarials | 1 | 2021 | 19 | 0.210 |
Why?
|
| Workflow | 1 | 2021 | 72 | 0.210 |
Why?
|
| Quinine | 1 | 2001 | 5 | 0.210 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 121 | 0.210 |
Why?
|
| Cobalt | 1 | 2001 | 29 | 0.210 |
Why?
|
| Axons | 2 | 2020 | 169 | 0.210 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 195 | 0.210 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2020 | 2 | 0.200 |
Why?
|
| Visual Prosthesis | 1 | 2020 | 4 | 0.200 |
Why?
|
| Osteosarcoma | 1 | 2022 | 157 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 1019 | 0.200 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 2019 | 36 | 0.200 |
Why?
|
| Sarcoma | 2 | 2017 | 205 | 0.200 |
Why?
|
| Neuropathology | 1 | 2020 | 3 | 0.200 |
Why?
|
| Blood Platelets | 1 | 2021 | 150 | 0.200 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2020 | 11 | 0.200 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2020 | 11 | 0.200 |
Why?
|
| Deltoid Muscle | 1 | 2020 | 2 | 0.200 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 29 | 0.200 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 98 | 0.200 |
Why?
|
| Smooth Muscle Tumor | 1 | 2020 | 4 | 0.190 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2020 | 73 | 0.190 |
Why?
|
| Organometallic Compounds | 1 | 2001 | 125 | 0.190 |
Why?
|
| Simvastatin | 2 | 2019 | 106 | 0.190 |
Why?
|
| Fasciitis | 1 | 2019 | 9 | 0.190 |
Why?
|
| Mucolipidoses | 1 | 2019 | 3 | 0.190 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 275 | 0.190 |
Why?
|
| Myosin Heavy Chains | 4 | 2019 | 88 | 0.190 |
Why?
|
| Synaptic Transmission | 2 | 2018 | 216 | 0.190 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2019 | 11 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 72 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 114 | 0.190 |
Why?
|
| Frozen Sections | 1 | 2019 | 47 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 47 | 0.190 |
Why?
|
| Mice, Transgenic | 8 | 2017 | 1507 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 365 | 0.190 |
Why?
|
| Orbital Diseases | 1 | 2019 | 21 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 2169 | 0.190 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2019 | 7 | 0.180 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 111 | 0.180 |
Why?
|
| Optic Chiasm | 1 | 2019 | 16 | 0.180 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2018 | 8 | 0.180 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 318 | 0.180 |
Why?
|
| Amyloidosis | 1 | 2020 | 88 | 0.180 |
Why?
|
| Theilovirus | 1 | 2019 | 39 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 274 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2008 | 2060 | 0.170 |
Why?
|
| Carcinogenesis | 1 | 2020 | 180 | 0.170 |
Why?
|
| Motor Cortex | 2 | 2017 | 189 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2019 | 174 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 254 | 0.170 |
Why?
|
| Inflammation | 3 | 2014 | 839 | 0.170 |
Why?
|
| Necrosis | 3 | 2014 | 190 | 0.170 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 110 | 0.170 |
Why?
|
| Motor Endplate | 2 | 2018 | 31 | 0.170 |
Why?
|
| Pregnancy | 2 | 2022 | 2701 | 0.170 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 83 | 0.170 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2015 | 44 | 0.170 |
Why?
|
| Influenza, Human | 1 | 2021 | 332 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 2324 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2021 | 2579 | 0.170 |
Why?
|
| Multiple Sclerosis | 1 | 2020 | 254 | 0.170 |
Why?
|
| Stem Cell Transplantation | 2 | 2016 | 176 | 0.170 |
Why?
|
| Visual Cortex | 1 | 2020 | 222 | 0.160 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2017 | 3 | 0.160 |
Why?
|
| Carrier Proteins | 3 | 2010 | 658 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2021 | 1513 | 0.160 |
Why?
|
| Medulloblastoma | 2 | 2009 | 36 | 0.160 |
Why?
|
| Spinal Stenosis | 1 | 2017 | 25 | 0.160 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2017 | 17 | 0.160 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2017 | 14 | 0.160 |
Why?
|
| Polyethylene | 1 | 2016 | 8 | 0.160 |
Why?
|
| Cartilage Diseases | 1 | 2016 | 16 | 0.160 |
Why?
|
| Osteolysis | 1 | 2016 | 14 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 402 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 1223 | 0.160 |
Why?
|
| Adenoma | 1 | 2019 | 232 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 1163 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2016 | 12 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2020 | 3147 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 377 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 45 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2016 | 288 | 0.150 |
Why?
|
| Phosphofructokinases | 1 | 2016 | 2 | 0.150 |
Why?
|
| Cells, Cultured | 7 | 2020 | 2772 | 0.150 |
Why?
|
| Dendrites | 1 | 2017 | 97 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1539 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2017 | 144 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2272 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2021 | 569 | 0.150 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2006 | 46 | 0.150 |
Why?
|
| Prognosis | 6 | 2021 | 3540 | 0.140 |
Why?
|
| Myostatin | 1 | 2015 | 3 | 0.140 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2015 | 12 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 629 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 143 | 0.140 |
Why?
|
| White Matter | 1 | 2016 | 70 | 0.140 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 54 | 0.140 |
Why?
|
| Meningioma | 1 | 2015 | 53 | 0.140 |
Why?
|
| Pandemics | 1 | 2021 | 624 | 0.140 |
Why?
|
| Inclusion Bodies | 1 | 2015 | 31 | 0.140 |
Why?
|
| Osteoma | 1 | 2014 | 5 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2017 | 199 | 0.140 |
Why?
|
| Aging, Premature | 1 | 2014 | 7 | 0.140 |
Why?
|
| Tubulin | 1 | 2015 | 58 | 0.140 |
Why?
|
| Femoral Neoplasms | 1 | 2014 | 24 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 683 | 0.130 |
Why?
|
| Protein Transport | 5 | 2019 | 408 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 561 | 0.130 |
Why?
|
| Biomarkers | 3 | 2012 | 1600 | 0.130 |
Why?
|
| Mice, Knockout | 6 | 2019 | 1903 | 0.130 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2014 | 28 | 0.130 |
Why?
|
| Fluoxetine | 1 | 2014 | 42 | 0.130 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 40 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 646 | 0.130 |
Why?
|
| Quadriceps Muscle | 1 | 2014 | 4 | 0.130 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2014 | 9 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 7 | 2017 | 3052 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 91 | 0.130 |
Why?
|
| Glycerol | 1 | 2013 | 29 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 131 | 0.130 |
Why?
|
| Caspase 7 | 1 | 2013 | 15 | 0.130 |
Why?
|
| Pigmentation | 1 | 2014 | 62 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 154 | 0.130 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2013 | 4 | 0.130 |
Why?
|
| Caspase 9 | 1 | 2013 | 47 | 0.130 |
Why?
|
| Radiation | 1 | 2013 | 15 | 0.120 |
Why?
|
| Cell Lineage | 1 | 2015 | 281 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2017 | 409 | 0.120 |
Why?
|
| Spinal Curvatures | 1 | 2013 | 7 | 0.120 |
Why?
|
| NIMA-Related Kinases | 1 | 2013 | 7 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 251 | 0.120 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2013 | 10 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2013 | 157 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 203 | 0.120 |
Why?
|
| Microscopy, Electron | 3 | 2021 | 496 | 0.120 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 1 | 2012 | 4 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2014 | 250 | 0.120 |
Why?
|
| Dysferlin | 4 | 2015 | 13 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.120 |
Why?
|
| Calpain | 1 | 2013 | 110 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 538 | 0.120 |
Why?
|
| Melanoma | 1 | 2017 | 431 | 0.120 |
Why?
|
| Pinealoma | 1 | 2012 | 4 | 0.120 |
Why?
|
| Cardiac Myosins | 2 | 2009 | 18 | 0.110 |
Why?
|
| Gene Silencing | 2 | 2013 | 163 | 0.110 |
Why?
|
| Extremities | 1 | 2013 | 161 | 0.110 |
Why?
|
| Kisspeptins | 1 | 2011 | 4 | 0.110 |
Why?
|
| Motor Activity | 1 | 2014 | 319 | 0.110 |
Why?
|
| Intracranial Aneurysm | 1 | 2013 | 154 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 173 | 0.110 |
Why?
|
| Dendritic Cells | 1 | 2015 | 419 | 0.110 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 58 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2013 | 155 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 152 | 0.110 |
Why?
|
| Gene Amplification | 1 | 2012 | 130 | 0.110 |
Why?
|
| DNA Damage | 1 | 2013 | 350 | 0.110 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 1 | 2011 | 4 | 0.110 |
Why?
|
| Choroid Plexus | 1 | 2011 | 12 | 0.110 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 11 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 680 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 176 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2012 | 150 | 0.100 |
Why?
|
| Lamin Type A | 1 | 2010 | 23 | 0.100 |
Why?
|
| Membrane Fusion | 1 | 2010 | 37 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2010 | 3 | 0.100 |
Why?
|
| Radiography | 3 | 2013 | 790 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 58 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 1615 | 0.100 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2010 | 15 | 0.100 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 28 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2015 | 451 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 723 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1328 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 450 | 0.100 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2010 | 26 | 0.100 |
Why?
|
| Hemangioma, Cavernous | 1 | 2011 | 68 | 0.100 |
Why?
|
| Keratins | 2 | 2012 | 63 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 44 | 0.100 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2010 | 53 | 0.100 |
Why?
|
| Aging | 1 | 2014 | 629 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 376 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1125 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 44 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 381 | 0.100 |
Why?
|
| Subarachnoid Space | 1 | 2009 | 17 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 154 | 0.100 |
Why?
|
| Homozygote | 2 | 2022 | 197 | 0.100 |
Why?
|
| Age Factors | 3 | 2014 | 1775 | 0.100 |
Why?
|
| KATP Channels | 1 | 2009 | 19 | 0.090 |
Why?
|
| Hypertrophy | 2 | 2015 | 62 | 0.090 |
Why?
|
| Sarcomeres | 1 | 2009 | 20 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 2764 | 0.090 |
Why?
|
| Lung | 2 | 2021 | 1092 | 0.090 |
Why?
|
| Receptors, Drug | 1 | 2009 | 54 | 0.090 |
Why?
|
| Brain Infarction | 1 | 2009 | 20 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2007 | 287 | 0.090 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 74 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2009 | 47 | 0.090 |
Why?
|
| Neocortex | 1 | 2010 | 91 | 0.090 |
Why?
|
| Oligodendroglioma | 1 | 2009 | 44 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 439 | 0.090 |
Why?
|
| Phenotype | 4 | 2014 | 2283 | 0.090 |
Why?
|
| Genome, Human | 1 | 2014 | 740 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 66 | 0.090 |
Why?
|
| Complement Activation | 1 | 2009 | 79 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 71 | 0.090 |
Why?
|
| Microcirculation | 1 | 2009 | 103 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2007 | 447 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 59 | 0.090 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2009 | 47 | 0.090 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2008 | 14 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 140 | 0.090 |
Why?
|
| Myelitis, Transverse | 1 | 2008 | 10 | 0.090 |
Why?
|
| Salivary Glands, Minor | 1 | 2008 | 9 | 0.090 |
Why?
|
| Submandibular Gland Diseases | 1 | 2008 | 9 | 0.090 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2009 | 116 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1421 | 0.090 |
Why?
|
| Cell Membrane | 2 | 2010 | 659 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 230 | 0.090 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 18 | 0.090 |
Why?
|
| Electromagnetic Fields | 1 | 2008 | 25 | 0.090 |
Why?
|
| Bronchi | 1 | 2009 | 227 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 3 | 2017 | 416 | 0.090 |
Why?
|
| Protein Binding | 4 | 2018 | 1443 | 0.080 |
Why?
|
| Ependymoma | 1 | 2007 | 16 | 0.080 |
Why?
|
| Neural Conduction | 2 | 2010 | 65 | 0.080 |
Why?
|
| Caprylates | 1 | 2007 | 11 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 516 | 0.080 |
Why?
|
| Fibrosis | 1 | 2008 | 190 | 0.080 |
Why?
|
| Sarcolemma | 3 | 2014 | 30 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 285 | 0.080 |
Why?
|
| Head | 1 | 2008 | 127 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2008 | 81 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 321 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2008 | 124 | 0.080 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 1067 | 0.080 |
Why?
|
| Dystrophin | 1 | 2007 | 20 | 0.080 |
Why?
|
| Arteries | 1 | 2008 | 164 | 0.080 |
Why?
|
| Endocytosis | 1 | 2008 | 175 | 0.080 |
Why?
|
| Cell Nucleus | 3 | 2019 | 567 | 0.080 |
Why?
|
| Amyloid | 1 | 2007 | 76 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 232 | 0.080 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 148 | 0.080 |
Why?
|
| Action Potentials | 1 | 2010 | 555 | 0.080 |
Why?
|
| Epilepsy | 1 | 2010 | 376 | 0.080 |
Why?
|
| Wilms Tumor | 1 | 2006 | 38 | 0.080 |
Why?
|
| Developmental Disabilities | 1 | 2008 | 192 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2008 | 462 | 0.080 |
Why?
|
| Muscles | 1 | 2007 | 184 | 0.080 |
Why?
|
| Muscle Weakness | 2 | 2021 | 60 | 0.080 |
Why?
|
| Microglia | 2 | 2017 | 89 | 0.070 |
Why?
|
| Chondrocalcinosis | 1 | 2006 | 8 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2007 | 344 | 0.070 |
Why?
|
| Synovial Membrane | 1 | 2006 | 27 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 186 | 0.070 |
Why?
|
| Chondrocytes | 1 | 2006 | 59 | 0.070 |
Why?
|
| Neurofibroma | 1 | 2005 | 11 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2006 | 150 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2009 | 310 | 0.070 |
Why?
|
| Heterozygote | 2 | 2018 | 359 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2007 | 234 | 0.070 |
Why?
|
| Age Distribution | 1 | 2006 | 199 | 0.070 |
Why?
|
| Crystallization | 1 | 2006 | 203 | 0.070 |
Why?
|
| Electric Stimulation | 2 | 2020 | 332 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2005 | 57 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2005 | 92 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2007 | 206 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 131 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2005 | 428 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2013 | 130 | 0.070 |
Why?
|
| Neuroimmunomodulation | 1 | 2004 | 11 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 365 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2010 | 611 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2009 | 617 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2014 | 698 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 831 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 1036 | 0.070 |
Why?
|
| Cell Line | 3 | 2019 | 2429 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1930 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 358 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 667 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 2277 | 0.060 |
Why?
|
| Steroids | 2 | 2018 | 163 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 232 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2022 | 589 | 0.060 |
Why?
|
| Paraparesis | 1 | 2002 | 4 | 0.060 |
Why?
|
| Radiculopathy | 1 | 2002 | 15 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2004 | 433 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 2348 | 0.060 |
Why?
|
| SOX9 Transcription Factor | 1 | 2022 | 22 | 0.060 |
Why?
|
| Neurons | 1 | 2010 | 1453 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2022 | 50 | 0.060 |
Why?
|
| Homeostasis | 2 | 2018 | 393 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2022 | 204 | 0.060 |
Why?
|
| Cell Movement | 2 | 2016 | 735 | 0.060 |
Why?
|
| Patch-Clamp Techniques | 2 | 2014 | 395 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 15 | 0.050 |
Why?
|
| Disease Progression | 3 | 2013 | 1432 | 0.050 |
Why?
|
| Proteins | 1 | 2007 | 758 | 0.050 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2021 | 14 | 0.050 |
Why?
|
| Protein Aggregates | 1 | 2021 | 20 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 381 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 588 | 0.050 |
Why?
|
| Integrin beta3 | 1 | 2021 | 30 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2008 | 1274 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 72 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 126 | 0.050 |
Why?
|
| Femur | 1 | 2021 | 108 | 0.050 |
Why?
|
| Molecular Conformation | 1 | 2001 | 95 | 0.050 |
Why?
|
| Phosphenes | 1 | 2020 | 5 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2001 | 330 | 0.050 |
Why?
|
| Hydrogen Bonding | 1 | 2001 | 144 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 303 | 0.050 |
Why?
|
| Apoptosis | 3 | 2014 | 1645 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 54 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2020 | 19 | 0.050 |
Why?
|
| Point Mutation | 1 | 2021 | 247 | 0.050 |
Why?
|
| Ovary | 1 | 2021 | 242 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2001 | 283 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2007 | 2168 | 0.050 |
Why?
|
| Pedigree | 2 | 2014 | 962 | 0.050 |
Why?
|
| Endosomes | 2 | 2010 | 79 | 0.050 |
Why?
|
| Pregnancy, Twin | 1 | 2019 | 7 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 489 | 0.050 |
Why?
|
| Seasons | 1 | 2021 | 234 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2020 | 87 | 0.050 |
Why?
|
| Lysosomes | 2 | 2010 | 109 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2019 | 36 | 0.050 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2019 | 25 | 0.050 |
Why?
|
| Electrodes, Implanted | 1 | 2020 | 163 | 0.050 |
Why?
|
| Nuclear Envelope | 2 | 2009 | 35 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 57 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2009 | 229 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2009 | 7467 | 0.050 |
Why?
|
| Twins | 1 | 2019 | 65 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 1183 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2001 | 479 | 0.050 |
Why?
|
| KRIT1 Protein | 1 | 2019 | 55 | 0.050 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.040 |
Why?
|
| Regeneration | 2 | 2010 | 139 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 74 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 167 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 49 | 0.040 |
Why?
|
| Macrophages | 2 | 2016 | 530 | 0.040 |
Why?
|
| Fetus | 1 | 2019 | 215 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 61 | 0.040 |
Why?
|
| Synaptic Vesicles | 1 | 2018 | 32 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2019 | 276 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 2 | 2009 | 219 | 0.040 |
Why?
|
| Cryoglobulinemia | 1 | 2017 | 6 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2018 | 277 | 0.040 |
Why?
|
| Sural Nerve | 1 | 2017 | 19 | 0.040 |
Why?
|
| Tics | 1 | 2017 | 4 | 0.040 |
Why?
|
| Cervical Cord | 1 | 2017 | 6 | 0.040 |
Why?
|
| Time Factors | 3 | 2014 | 5087 | 0.040 |
Why?
|
| Myopia | 1 | 2017 | 10 | 0.040 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2017 | 16 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2018 | 492 | 0.040 |
Why?
|
| Inhibins | 1 | 2017 | 36 | 0.040 |
Why?
|
| Genotype | 2 | 2014 | 1812 | 0.040 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 11 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2021 | 487 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2018 | 173 | 0.040 |
Why?
|
| Thymus Hyperplasia | 1 | 2016 | 3 | 0.040 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 31 | 0.040 |
Why?
|
| Receptors, CCR4 | 1 | 2016 | 3 | 0.040 |
Why?
|
| Melanocytes | 1 | 2017 | 55 | 0.040 |
Why?
|
| Arthroplasty, Replacement, Ankle | 1 | 2016 | 17 | 0.040 |
Why?
|
| Pyramidal Cells | 1 | 2017 | 73 | 0.040 |
Why?
|
| tau Proteins | 1 | 2016 | 31 | 0.040 |
Why?
|
| Gout | 1 | 2017 | 74 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 600 | 0.040 |
Why?
|
| Face | 1 | 2017 | 120 | 0.040 |
Why?
|
| Rats | 2 | 2013 | 3904 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 731 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2020 | 687 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 117 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 824 | 0.040 |
Why?
|
| Follistatin | 1 | 2015 | 6 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2015 | 48 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2016 | 70 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 19 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 959 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 76 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2018 | 422 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 519 | 0.030 |
Why?
|
| Kyphosis | 1 | 2014 | 12 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2015 | 109 | 0.030 |
Why?
|
| Gliosis | 1 | 2014 | 31 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 180 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2015 | 90 | 0.030 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2014 | 31 | 0.030 |
Why?
|
| LIM Domain Proteins | 1 | 2014 | 25 | 0.030 |
Why?
|
| Longevity | 1 | 2014 | 44 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 918 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 232 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2015 | 159 | 0.030 |
Why?
|
| Caveolin 3 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 93 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 160 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Convection | 1 | 2013 | 12 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 843 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 33 | 0.030 |
Why?
|
| Vaccination | 1 | 2015 | 237 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 3026 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 265 | 0.030 |
Why?
|
| Algorithms | 2 | 2014 | 1776 | 0.030 |
Why?
|
| Ferric Compounds | 1 | 2013 | 36 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2014 | 254 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2014 | 253 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 354 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2014 | 261 | 0.030 |
Why?
|
| Histones | 1 | 2014 | 294 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2014 | 184 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2012 | 47 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2012 | 49 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 690 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 558 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 356 | 0.030 |
Why?
|
| Polymers | 1 | 2013 | 193 | 0.030 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2012 | 34 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 1095 | 0.030 |
Why?
|
| Cell Division | 1 | 2013 | 688 | 0.030 |
Why?
|
| Rabbits | 1 | 2012 | 632 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2015 | 508 | 0.030 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2010 | 5 | 0.030 |
Why?
|
| Bicuculline | 1 | 2010 | 18 | 0.030 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2010 | 15 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2010 | 38 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2010 | 36 | 0.030 |
Why?
|
| N-Methylaspartate | 1 | 2010 | 51 | 0.030 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2010 | 45 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2010 | 116 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 5122 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2012 | 236 | 0.030 |
Why?
|
| Electrodiagnosis | 1 | 2010 | 7 | 0.030 |
Why?
|
| Mice, Inbred mdx | 1 | 2010 | 10 | 0.030 |
Why?
|
| Cardiotoxins | 1 | 2010 | 3 | 0.030 |
Why?
|
| Pupil | 1 | 2010 | 18 | 0.030 |
Why?
|
| Cell Survival | 1 | 2013 | 959 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2010 | 76 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 443 | 0.030 |
Why?
|
| Peripheral Nerves | 1 | 2010 | 35 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2010 | 31 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Myoblasts, Skeletal | 1 | 2009 | 3 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2009 | 21 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 348 | 0.020 |
Why?
|
| Sulfonylurea Receptors | 1 | 2009 | 48 | 0.020 |
Why?
|
| Neurosurgery | 1 | 2011 | 79 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2010 | 126 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2010 | 269 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2441 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 254 | 0.020 |
Why?
|
| Lamins | 1 | 2008 | 6 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 984 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 261 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 538 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 143 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1534 | 0.020 |
Why?
|
| Transferrin | 1 | 2008 | 19 | 0.020 |
Why?
|
| DNA | 1 | 2014 | 1250 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1098 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2008 | 39 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2008 | 33 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 107 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 510 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 2008 | 29 | 0.020 |
Why?
|
| Magnetics | 1 | 2008 | 44 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2009 | 242 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2009 | 271 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 111 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 222 | 0.020 |
Why?
|
| Aldehydes | 1 | 2007 | 14 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2008 | 206 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 332 | 0.020 |
Why?
|
| Micelles | 1 | 2007 | 45 | 0.020 |
Why?
|
| Pentosyltransferases | 1 | 2007 | 35 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2008 | 349 | 0.020 |
Why?
|
| Asparagine | 1 | 2007 | 29 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2007 | 89 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2008 | 75 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2009 | 254 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2007 | 63 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2008 | 256 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 390 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 652 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2008 | 145 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2006 | 119 | 0.020 |
Why?
|
| Gelsolin | 1 | 2005 | 11 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 44 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2007 | 752 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2303 | 0.020 |
Why?
|
| Parietal Lobe | 1 | 2006 | 113 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 244 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2007 | 334 | 0.020 |
Why?
|
| Niacinamide | 1 | 2005 | 116 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2005 | 63 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2005 | 108 | 0.020 |
Why?
|
| Genes, Synthetic | 1 | 2004 | 7 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 851 | 0.020 |
Why?
|
| Lac Operon | 1 | 2004 | 44 | 0.020 |
Why?
|
| Cerebellar Ataxia | 1 | 2004 | 16 | 0.020 |
Why?
|
| Doxycycline | 1 | 2004 | 26 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 120 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2004 | 57 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 51 | 0.020 |
Why?
|
| Echocardiography | 1 | 2009 | 874 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2004 | 87 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2004 | 258 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 568 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 1176 | 0.020 |
Why?
|
| Astrocytes | 1 | 2004 | 133 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 2059 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 204 | 0.020 |
Why?
|
| Leukocytes | 1 | 2004 | 192 | 0.020 |
Why?
|
| Pyridines | 1 | 2005 | 299 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 155 | 0.020 |
Why?
|
| Cerebellum | 1 | 2004 | 234 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 550 | 0.010 |
Why?
|
| Stroke | 1 | 2008 | 769 | 0.010 |
Why?
|